Protein-energy wasting is characterized by undernutrition unrelieved by nutritional therapy and increased fat and protein catabolism.
Serum parathyroid hormone levels significantly increased from 42.2 to 114.8 pmol/L over 12 months in patients who halted the calcimimetic drug.
Pre-operative parathyroid hormone and calcium levels and pruritus are significantly associated with development of severe hypocalemia.
Anemia control may be one more reason to treat elevated parathyroid hormone levels.
Predictors of hungry bone syndrome after parathyroidectomy include lower pre- and post-op calcium levels, according to a new study.
Control of parathyroid hormone did not differ markedly at 48 and 72 hours after in-center HD compared with 24 hours after daily oral administration of 30 mg cinacalcet.
Levels of the bone turnover markers CTX and P1NP declined over approximately 6 months of treatment patients with CKD and secondary hyperparathyroidism.
Researchers found no significant difference between ergocalciferol and cholecalciferol in maintaining levels of vitamin D, parathyroid hormone, and calcium.
The authors of a new review suggest more dialysis patients could benefit from parathyroidectomy.
In a study, intact parathyroid hormone levels fell by nearly 10% over 6 months in hemodialysis patients who received intensive treatment for hyperphosphatemia.
Panel focuses on diagnosing and testing of CKD-MBD and treatment of the CKD-MBD that emphasizes decreasing phosphate, maintaining calcium, and addressing elevated PTH in adults with CKD stage G3a to G5.
Abnormal calcium-phosphate metabolism appears to be an important pathogenic factor in the development of vascular calcification in patients with chronic kidney disease.
In patients with stage 5 chronic kidney disease, lupus anticoagulant and combined thrombophilia occur more frequently in those with versus without calciphylaxis, case-control study shows.
iPTH significantly correlated with measures of diastolic dysfunction in patients with non-dialysis chronic kidney disease.
Patients with high alkaline phosphatase prior to PTx should be treated aggressively after surgery to prevent postoperative hypocalcemia, researchers conclude.
In 2 studies, parathyroid hormone (PTH) values 20 minutes after parathyroidectomy predicted PTH levels for 5 years.
In a study, intact parathyroid hormone levels below 60 and above 1500 pg/mL were associated with nearly double the risk of all-cause mortality.
In a small study, more than half of patients with secondary hyperparathyroidism had a greater than 25% drop in parathyroid hormone levels following ethanol injection therapy.
Nearly 86% of diabetic nephropathy patients from an Egyptian outpatient center had elevated iPTH levels.
Hypocalcemia developed in 58.3% of study participants within the first 16 weeks and, in most cases, resolved within 14 days with no changes in treatment.
Patients reported less skin itching, joint pain, and muscle weakness after surgery.
ESRD patients with SHPT undergoing surgery had a 26% lower risk for all-cause mortality compared with medical management.
Secondary hyperparathyroidism may have a detrimental effect on successful arteriovenous fistula creation, researcher says.
In a pilot study, investigators observed no harmful effects from etelcalcetide injection, and 5 of 10 of patients had a greater than 50% decline in PTH levels.
Therapy with paricalcitol alone achieved the greatest decline in intact parathyroid hormone among hemodialysis with secondary hyperparathyroidism.
High levels of parathyroid hormone and fibroblast growth factor 23 in CKD patients are associated with need for renal replacement therapy or a 50% or greater decline in eGFR.
Intact parathyroid hormone levels decline in proportion with SHPT severity in patients taking the drug.
Cholecalciferol can also correct vitamin D deficiency in patients with chronic kidney disease.
Dialysis patients treated with a low protein diet with keto analogues had lower levels of parathyroid hormone than those on a normal diet, meta-analysis shows.
By the third month of treatment, 59% of etelcalcetide recipients had reached target iPTH levels of 60 to 240 pg/mL compared with just 1.3% of placebo recipients.
Renal and Urology News Articles
- Aggressive Therapy Warranted for Gleason 10 Prostate Cancer
- PET/CT May Improve Imaging of Recurrent Prostate Cancer
- Adding MRI Does Not Boost Prostate Cancer Upgrading Rate
- Both High and Low Uric Acid Levels Tied to Higher Mortality
- Trulicity Labeling Updated to Include Data on T2D Patients With CKD
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)